Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...

ideaPoint and WideTrial Launch Global Expanded Access Platform for COVID-19 Medicines BOSTON, March 31, 2020 (GLOBE NEWSWIRE) -- Anaqua’s ideaPoint, a provider of medical affairs and innovation management solutions, today announced a strategic partnership with clinical data company...

Spend on HEOR Studies Expected to Grow at 9.7% Through 2020 CARY, NC--(Marketwired - July 19, 2016) - Industry Standard Research has released a new report, "Late Phase Study Trends and Market Outlook (2016-2020)," containing findings focused on current...